Pew, together with 30 other organizations—including patient advocacy groups, medical and public health associations, and industry representatives—sent a letter to Congress on Feb. 23 calling on members of the Committee on Health, Education, Labor, and Pensions to consider legislation that would help advance the development of new antibiotics for seriously ill patients with unmet medical needs.
The bipartisan Promise for Antibiotics and Therapeutics for Health (PATH) Act calls for a new, limited population antibacterial drug (LPAD) pathway—a unique mechanism the Food and Drug Administration could use to review and approve new antibacterial drugs for specific, limited populations of patients with serious and life-threatening bacterial infections that are resistant to current treatments.